Compound 6(University of Health and Allied Sciences)

A series of 2,3‐dihydrobenzo[b][1,4]thiazepine derivatives have been synthesized and characterized using IR, NMR, GC‐MS and microanalysis. The compounds were found to exhibit variable activity against Escherichia coli , Klebsiella pneumoniae , Enterococcus faecalis and Salmonella typhi with MIC values ranging from 1.88–15 mg/mL. The best activity was observed in compounds 4 and 6 with MIC of 1.875 mg/mL against E . faecalis. Compound 6 was also the most active against S . aureus with MIC of 1.875 mg/mL. The in silico computational docking revealed that the compounds have excellent binding to both multiple targets of E. coli and Staphylococcus aureus dihydrofolate reductase enzymes (PDB ID: 6XG5 and 6P9Z) and good binding to the S. aureus dihydropteroate synthase enzyme (PDB ID: 1ad4). The computational pharmacokinetic study showed that the highly orally bioavailable compounds were not P‐gp (p‐glycoprotein substrate). The compounds were found to be excellent hERG blockers.